Robust Neutralizing VHH Nanobodies to Tackle the Spread of Lethal SARS-CoV-2 Variants

A highly infectious virus, Novel SARS-CoV-2, which originated in late 2019, causes the disease COVID19. The virus spread with extreme speed all around the world and led to over 145 million cases of COVID19 disease, which has high infection and mortality rates.

The global life science community is expediting research to find safe and efficient antiviral therapies. These include:

  • Vaccines
  • Antivirals
  • Antibody-based therapies

Finding safe and effective anti sarscov2 therapeutics is crucial to curb the spread of the virus and treat the population who are already infected.

As with a number of other zoonotic viruses, SARS-CoV-2 expresses key surface Spike (S) proteins made up of the S1 and S2 subunits. The interaction between the virus and the host cell receptor is facilitated by the spike(S) protein and the human Angiotensin-converting enzyme 2 (ACE2) receptor.

Conformational changes which are brought about by the virus’s genome machinery on the Spike proteins due to mutation supply an evolutionary edge to the virus by producing variants with enhanced binding potential and options to evade the potent neutralizing antibodies (Nabs) which are generated by the host’s immune response.

Novel single heavy chain only antibodies called Nanobodies (Nbs) are produced by the Camelid family. These are small (~15kDa), stable, and easily bioengineered to create antibodies that have high specificity to selected antigens.

As a result of their high solubility, low cost, efficient microbial production and bioengineering potential to target upcoming Sars-CoV-2 variants, the development of these highly potent and specific anti-Sars-coV-2 NBS may open clinical avenues for the development of safe, cost-effective and quick therapeutics and point of care diagnostics.

SignalChem has invested heavily in the research and development of COVID19 products since the start of the COVID-19 pandemic to give the life science community vital research tools to expedite COVID19 research.

SignalChem joined with four other Canadian companies to create a coalition to identify and manufacture nanobodies-special antibodies, which are only found in llamas and sharks and are activated in the immune response against COVID-19.

In order to expedite anti-Sars-Cov-2 research and therapeutics, SignalChem has produced three effective recombinant Llama VHH nanobodies.

The Anti-2019-nCoV Spike Protein Neutralizing Nanobodies were mainly raised in Llama, and then recombinant versions were expressed by utilizing CHO cells for studying neutralization of SARS-CoV-2 and for identifying the SARS-CoV-2 spike protein.

The nanobodies were validated by SignalChem’s team of in-house scientists using functional ELISA for their neutralization potential against wild-type RBD and new variants like the N501Y variant, triple mutant (K417N, E484K, N501Y).

Product Name: Anti-2019-nCoV Spike Protein Neutralizing Nanobody (NBX20038)

Catalog No: C19S1-652L

Product Info: Recombinant Llama VHH to study Sars-CoV-2 neutralization and identification of 2019-nCoV spike protein.

Binding ability measured in a functional ELISA. Anti-2019-nCoV Spike Protein Neutralizing Nanobody (C19S1-652L) binds to 2019-nCoV Spike protein RBD (C19SD-G241H).

Figure 1. Binding ability measured in a functional ELISA. Anti-2019-nCoV Spike Protein Neutralizing Nanobody (C19S1-652L) binds to 2019-nCoV Spike protein RBD (C19SD-G241H). Image Credit: SignalChem Biotech, Inc.

Product Name: Anti-2019-nCoV Spike Protein Neutralizing Nanobody (NBX20025)

Catalog No: C19S1-653L

Product Info: Recombinant Llama VHH to study Sars-CoV-2 neutralization and identification of 2019-nCoV spike protein.

Binding ability measured in a functional ELISA. Anti-2019-nCoV Spike Protein Neutralizing Nanobody (C19S1-653L) binds 2019-nCoV Spike protein RBD (C19SD-G241H).

Figure 2. Binding ability measured in a functional ELISA. Anti-2019-nCoV Spike Protein Neutralizing Nanobody (C19S1-653L) binds 2019-nCoV Spike protein RBD (C19SD-G241H). Image Credit: SignalChem Biotech, Inc.

Product Name: Anti-2019-nCoV Spike Protein Neutralizing Nanobody (NBX20014)

Catalog No: C19S1-654L

Product Info: Recombinant Llama VHH to study Sars-CoV-2 neutralization and identification of 2019-nCoV spike protein.

Binding ability measured in a functional ELISA. Anti-2019-nCoV Spike Protein Neutralizing Nanobody (C19S1-654L) binds 2019-nCoV Spike protein RBD (C19SD-G241H).

Figure 3. Binding ability measured in a functional ELISA. Anti-2019-nCoV Spike Protein Neutralizing Nanobody (C19S1-654L) binds 2019-nCoV Spike protein RBD (C19SD-G241H). Image Credit: SignalChem Biotech, Inc.

SignalChem is a global leader in cell signaling and protein engineering and, since the outbreak of the virus, has been researching new coronavirus. Their scientists have invested their resources in understanding the protein interaction map of the SARS-CoV-2 to engineer active recombinant SARS-CoV-2 and human proteins successfully.

SignalChem aims to give other researchers these crucial pieces of the puzzle, which are essential for their drug discovery research projects around the globe.

SignalChem has already initiated projects and is developing expression systems of key COVID-19 related proteins, including hot drug targets such as proteases and non-structural proteins (NSPs) with the help of AI drug development software and advanced engineering technology.

These catalytically active proteins are described as fully functional and ready to be utilized in research projects for the development of drugs directed against SARS-CoV-2 and other coronavirus infections.

About SignalChem Biotech Inc.

SignalChem is a biotech company focused on the research, development, and production of innovative and high-quality human recombinant cell signaling products.

Throughout the years, Signalchem has capitalized on its core expertise in cellular signaling, molecular biology, and protein biochemistry to generate more than 2,000 functional protein products and has established itself as the leader in the industry to produce highly active human recombinant signaling enzymes, especially protein kinases, disease-related mutant kinases, lipid kinases, epigenetic enzymes, ubiquitination-related enzymes, and neurodegenerative disease-related enzymes and proteins.

SignalChem strives to support scientists in academia, pharma and biotech companies around the world by creating effective research tools to advance the basic research in life sciences and to facilitate the efforts in drug discovery and development.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: May 25, 2021 at 11:14 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    SignalChem Biotech Inc.. (2021, May 25). Robust Neutralizing VHH Nanobodies to Tackle the Spread of Lethal SARS-CoV-2 Variants. News-Medical. Retrieved on August 04, 2021 from https://www.news-medical.net/whitepaper/20210506/Robust-Neutralizing-VHH-Nanobodies-to-Tackle-the-Spread-of-Lethal-SARS-CoV-2-Variants.aspx.

  • MLA

    SignalChem Biotech Inc.. "Robust Neutralizing VHH Nanobodies to Tackle the Spread of Lethal SARS-CoV-2 Variants". News-Medical. 04 August 2021. <https://www.news-medical.net/whitepaper/20210506/Robust-Neutralizing-VHH-Nanobodies-to-Tackle-the-Spread-of-Lethal-SARS-CoV-2-Variants.aspx>.

  • Chicago

    SignalChem Biotech Inc.. "Robust Neutralizing VHH Nanobodies to Tackle the Spread of Lethal SARS-CoV-2 Variants". News-Medical. https://www.news-medical.net/whitepaper/20210506/Robust-Neutralizing-VHH-Nanobodies-to-Tackle-the-Spread-of-Lethal-SARS-CoV-2-Variants.aspx. (accessed August 04, 2021).

  • Harvard

    SignalChem Biotech Inc.. 2021. Robust Neutralizing VHH Nanobodies to Tackle the Spread of Lethal SARS-CoV-2 Variants. News-Medical, viewed 04 August 2021, https://www.news-medical.net/whitepaper/20210506/Robust-Neutralizing-VHH-Nanobodies-to-Tackle-the-Spread-of-Lethal-SARS-CoV-2-Variants.aspx.

Other White Papers by this Supplier